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Volume 53, Number 3 Abstracts 879The Ectatic Aorta: No Benefit in Surveillance
Gibbs DMR, Brown MJ, Hussey G, Naylor AR. Ann Vasc Surg 2010;24:
908-11.
Conclusion: Patients with an abdominal aorta diameter of between 25
and 30 mm identified on a screening study for possible abdominal aortic
aneurysm (AAA) do not require further surveillance for at least 5 years.
Summary: Ultrasound screening of men aged 65 years appears
effective in reducing AAA-related mortality and cost (Ashton HA, et al,
Lancet 2002:360:1531-9). There is, however, little consensus on follow-up
of the so-called ectatic aorta. This study defined an ectatic aorta as 25 to 30
mm in anterior-posterior (AP) diameter. As many as one-third of the
patients screened for AAA will have an “ectatic” aorta (Devaraj S, et al, Ann
R Coll Surg Engl 2008;90:477-82). The authors sought to determine if
patients with aortic diameters between 25 and 30 mm should have contin-
ued surveillance or if they could be discharged from follow-up ultrasound
screening.
This was a retrospective study of data prospectively collected as part of
a Liecestershire AAA screening program. The program has been in place
since 1996 and screens men aged65 years with a single ultrasound scan of
the aorta. Patients with an AP diameter of the aorta25 mm are discharged
from further screening. Those with aortas 25 mm in diameter enter the
surveillance program, with ultrasound scans every 12 months in patients
with aortas of 25 to 29 mm, every 6 months in patients with aortas between
30 and 49mm, and every 3 months when the aortic diameter is between and
50 and 52 mm. For this study, the authors used patients with an initial AAA
diameter of 25 to 30 mm who had undergone two or more surveillance
scans. There were 345 patients analyzed and the primary end point was death
from AAA rupture, presentation with rupture, or referral for elective repair.
The mean follow-up was 4.25 years (range, 1-11 years). At 5 years of
surveillance, there was a 97% freedom from death from rupture or referral for
repair.
Comment: For screening to be both effective and cost effective there
must be identification of appropriate subgroups of patients where a reason-
able yield of the screening process is anticipated. One can certainly argue
over what is “a reasonable yield.” However, it is difficult to argue that
continued close surveillance of patients with abdominal aortas between 25
and 30 mm has any hope of being cost effective. The information provided
here should be useful for those designing and implementing AAA screening
programs in their communities.
Effect of Celiprolol on Prevention of Cardiovascular Events in Vascular
Ehlers-Danlos Syndrome: A Prospective Randomized, Open Blinded-
Endpoints Trial
Ong K-T, Perdu J, DeBacker J, et al. Lancet 2010;376:1476-84.
Conclusion: Celiprolol appears effective in preventing major compli-
cations in patients with vascular Ehlers-Danlos syndrome.
Summary: Ehlers-Danlos syndrome is a heterogeneous group of con-
nective tissue disorders. It results from a number of mutations in the
COL3A1 gene that cause defects in pro1 (III) chain of collagen type 2. The
vascular form of Ehlers-Danlos is the most severe variant of Ehlers-Danlos
and is autosomal dominant. Median survival is 40 to 50 years. Major
complications include vascular dissection or rupture or rupture of hollow
organs (uterus, intestine). Complications are usually seen by age 20 years
and by age 40, 90% of patients have sustained a major event.
Vascular Ehlers-Danlos patients have decreased intima-media thickness
(IMT). (Boutouyie P, et al, Circulation 2004;109:1530-35). Decreases in
IMT may lead to decreased resistance to mechanical stress. The authors
proposed that treatment with celiprolol may prevent vascular events associ-
ated with Ehlers-Danlos syndrome by reducing heart rate and therefore
pulsatile mechanical stresses on weakened collagen fibers in the arterial wall
of patients with Ehlers-Danlos syndrome.
The Beta-Blockers in Ehlers-Danlos Syndrome Treatment (BBEST)
trial used a multicenter randomized open-trial design but with blinded
evaluation of clinical events. Patients with clinical Ehlers-Danlos syndrome
using the Villefranche diagnostic criteria were identified and randomly
assigned to treatment with celiprolol or no treatment. There were 53
patients included in the study and 33 had proven mutations in COL3A1.
Mean age at study entry was 35  12 years. Female/male ratio was 2:1.
Fifty-five percent had previous clinical events, and 21% had a family history
of clinical events related to Ehlers-Danlos. Patients were randomly assigned
to celiprolol or no treatment with stratification by age (32 or 32 years).
Celiprolol was up titrated every 6 months by steps of 100 mg to a maximum
of 400 mg twice daily. Primary end points were arterial events, rupture, or
dissection, fatal or not.
Of the 53 patients in the study, 25 were assigned to celiprolol and 28 to
the control group. Mean follow up was 47  5 months. The trial was
stopped early for treatment benefit. Primary end points were reached by 5
(20%) in celiprolol group and by 14 (50%) in the control group (hazard
ratio, 0.36; 95% CI, 0.15-0.88; P  .040). Adverse events included severe
fatigue in one patient after starting celiprolol at 100 mg daily and mild
fatigue in two patients related to dose up titration.
i
uComment: The trial suggests benefit of prevention of major compli-
ations of Ehlers-Danlos syndrome in patients with a clinical diagnosis of
hlers-Danlos. Subgroup analysis indicates equal benefit in patients with
nd without proven COL3A1 mutation. The authors found celiprolol did
ot decrease brachial systolic or diastolic pressures or heart rate, making it
nlikely the protective effect of celiprolol was mediated through blood
ressure lowering. The authors postulated the mechanism of action of
eliprolol in Ehlers-Danlos syndrome may be through effect on transform-
ng growth factor- and collagen synthesis. Results of the study must be
nterpreted with caution, because not all patients in the study were positive
or proven genetic mutations associated with Ehlers-Danlos syndrome.
evertheless, all included patients met clinical criteria for Ehlers-Danlos
yndrome and the results in the mutation-positive and mutation-negative
atients were similar, although that analysis was not prespecified in the study
esign.
ate Outcomes of Endovascular and Open Revascularization for Non-
therosclerotic Renal Artery Disease
am SW, Kumar SR, Wang BR, et al. Arch Surg 2010;145:832-9.
Conclusion: In patients with nonatherosclerotic renal artery disease
NARAD), open revascularization results in superior 1- and 5-year out-
omes compared with endovascular management.
Summary: Fibromuscular dysplasia and Takayasu arteritis are the most
ommon etiologies of NARAD leading to hypertension. Open or endovas-
ular revascularization is preferred over medical management alone in pa-
ients with severe hypertension associated with NARAD. Percutaneous
ransluminal angioplasty (PTA) is generally considered first-line therapy for
bromuscular disease, whereas open revascularization is generally thought
o be the best treatment for patients with Takayasu arteritis.
The purpose of this report was to evaluate long-term outcomes of
ndovascular and open treatment of NARAD. This was a retrospective
eview of 55 patients (47 women), with a mean age of 40 years. Underlying
isease processes included Takayasu arteritis in 31 patients and fibromuscu-
ar dysplasia in 24. Open revascularization was compared with renal artery
TA, with and without stenting, for primary, primary assisted, and second-
ry patency rates as well as blood pressure, antihypertensive medication
equirements, renal function, and mortality. Among the 79 renal artery
nterventions performed were 59 aortorenal bypasses (16 ex vivo), 3 visceral-
o-renal artery bypasses, 5 nephrectomies, and 12 endovascular percutane-
us revascularizations, 4 of which included stent placement. There were no
rocedural deaths.Mean follow-upwas 75months. Rates of primary patency
t 1, 3, and 5 years for any intervention were 87%, 75% and 75%, respectively.
rimary, primary assisted, and secondary patency rates were 92%, 86%, and
6%, respectively. Primary patency rates for endovascular interventions at 1,
, and 5 years were 73%, 49%, and 49%. Primary assisted/secondary patency
ates for endovascular interventions were 83%, 83%, and 83% at 1, 3, and 5
ears. At 1, 3, and 5 years, primary patency rates for open revascularization
ere 91%, 80%, and 80%. Primary assisted/secondary patency rates for open
nterventions at 1, 3 and 5 years were 94%, 87%, and 87%, respectively. Open
nd endovascular interventions both resulted in improvements in blood
ressure and the number of antihypertensive medications compared with
reintervention values (all P .05). Revascularization also improved serum
reatinine levels and estimated glomerular filtration rate (both P .05). The
- and 10-year actuarial survival rates were 94% and 78%, respectively.
Comment: The authors demonstrated open and endovascular inter-
ention can be safe and effective in management of renal artery-mediated
ypertension and renal dysfunction associated with NARAD. The patients
re not randomized, and any conclusions are somewhat weakened by the
tudy design, but in general, the data indicate primary open revasculariza-
ion, when compared with endovascular intervention, results in superior
utcome with respect to patency with equivalent safety. The authors’
onclusion is that open revascularization should be considered selectively as
rst-line of therapy for NARAD in the young patient with moderate to
omplex renal artery disease. This conclusion is clearly suggested but not
onfirmed by the data.
isk of Symptomatic DVT Associated with Peripherally Inserted Cen-
ral Catheters
vans RS, Sharp JH, Linford LH, et al. Chest 2010;138:803-10.
Conclusion: Increasing catheter size, prior deep vein thrombosis
DVT), and surgery lasting1 hour identify patients at risk for peripherally
nserted central catheter (PICC)-associated DVT.
Summary: PICCs are safe and cost-effective for providing long-term
ntravenous access. PICC catheters, however, are also associated with the
evelopment of catheter-associated DVT. The authors sought to identify
isk factors for PICC-associated DVT. This was a 1-year prospective obser-
ational study of PICC insertions in a 456-bed tertiary referral hospital with
level 1 trauma center. All patients with one or more PICC insertions were
ncluded. PICC catheters were placed by certified PICC team members
sing a consistent and replicated approach for vein selection and insertion. A
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March 2011880 Abstractstotal of 2014 PICCs were inserted during 1879 distinct hospitalizations in
1728 distinct patients, yielding a total of 15,115 days of PICC placement.
Most catheters were placed in the right arm (76.9%), and most were placed
in the basilic vein (74%). Most were double-lumen 5F (75.3%). Of the 2014
PICC insertions 60 in 57 distinct patients (3%) developed DVT in the
cannulated or adjacent veins. Factors associated with PICC associated DVT
included prior DVT (odds ratio [OR], 9.92; P .001), use of double-lumen
5F catheters (OR, 7.54; P .05), triple-lumen 6F catheters (OR, 19.5; P
.01), and prior surgery duration 1 hour (OR, 1.66; P  .1).
Comment: Assessment for DVT in the patients in this study occurred
only in symptomatic patients. Therefore, the actual true incidence of PICC-
associated DVT is likely to be much higher than that documented. It is
doubtful the clinical correlates associated with PICC-induced DVT (prior
DVT and surgery lasting1 hour) will have much impact on the selection of
patients for PICC placement. Physicians may, however, choose to treat
patients with these identified correlates with enhanced prophylaxis after
PICC placement. The data would also suggest it is important to minimize
the size of the catheter to reduce the development of symptomatic PICC-
associated DVT.
Short-term Outcome After Stenting Versus Endarterectomy for Symp-
tomatic Carotid Stenosis: A Preplanned Meta-analysis of Individual
Patient Data
The Carotid Stenting Trialists’ Collaboration. Lancet 2010;376:1062-73.
Conclusion: Stenting for symptomatic internal carotid artery (ICA)
stenosis should be avoided in patients aged70 years but might be as safe as
carotid endarterectomy (CEA) in younger patients with symptomatic ICA
stenosis.
Summary: Three large government-sponsored European trials—the
Endarterectomy versus Angioplasty in Patients with Symptomatic Severe
Carotid Stenosis (EVA- 3S) trial, the Stent-Protected Angioplasty versus
Carotid Endarterectomy (SPACE) trial, and the International Carotid
Stenting Study (ICSS)—evaluated CEA vs carotid artery stenting (CAS) in
symptomatic patients with standard surgical risk. These trials indicated a
higher periprocedural risk of stroke with CAS than with CEA. However, the
number of patients in each trial was insufficient to establish the relative
merits of stenting vs endarterectomy in relevant subgroups of patients. The
i
anvestigators of EVA-3S, SPACE, and ICSS therefore established the Ca-
otid Stenting Trialists’ Collaboration anticipating a meta-analysis to com-
are the safety and efficacy of CEA and CAS in predefined subgroups of
atients from the trials. The pooled data of 3433 patients with symptomatic
CA stenosis was analyzed with fixed effect binomial regression models
djusted for source trial. The primary outcome event was any stroke or
eath. Intention-to-treat and per-protocol analyses were performed. Pa-
ient-specific variables analyzed included age, sex, diabetes, hypertension,
ype of recent ipsilateral ischemic event, degree of ipsilateral carotid stenosis,
he presence of contralateral severe carotid stenosis or occlusion, and other
ariables.
The intention-to-treat analysis showed that in the first 120 days after
andomization, the primary end point of any stroke or death occurred
ignificantly more often in the CAS group (153 of 1725 [8.9%]) than in the
EA group (99 of 1708 [8.9%]; RR, 1.53, 95% CI, 1.20-1.95; P .0006).
he absolute risk difference was 3.2% (1.4%-4.9%). Age was the only
ubgroup variable analyzed that effected the risk of stroke in the CAS vs CEA
atients. In patients aged70 years, the estimated 120-day risk of stroke or
eath was 50 of 869 patients (5.8%) in the CAS group and 48 of 843 (5.7%)
n the CEA group (RR, 1.0; 95%CI, 0.68-1.47). In patients aged70 years,
stimated risk of CAS was twice that of CEA (103 of 856 [12.0%] vs 51 of
65 [5.9%]; RR, 2.4; 95% CI, 1.48-2.82; categoric interaction P  .0053,
rend interaction P  .0014). In the per-protocol analysis, risk estimates of
troke or death30 days of treatment among patients70 years were 43 of
51 patients (5.1%) in the CAS group and 37 of 821 patients (4.5%) in the
EA group (RR, 1.11; 95% CI, 0.73-1.71). For those aged 70 years,
stimates were 87 of 823 patients (10.5%) in the CAS group and 36 of 824
atients (4.4%) in the CEA group (RR, 2.41; 95% CI, 1.65-3.51; categoric
nteraction P  .0078, trend interaction P  .0013).
Comment: The European investigators showed significant insight in
he planning of this preplanned meta-analysis. These data, in combination
ith the recently reported CREST data, strongly suggest CEA is the
referred treatment for patients with symptomatic carotid stenosis who are
ged 70 years. It is important to remember, however, that the data apply
nly to patients at standard surgical risk. These are short-term data, and the
elative efficacy of the two procedures for long-term stroke prevention both
n symptomatic and asymptomatic patients was not addressed by this meta-
nalysis.
